Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States of America.
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, United States of America.
J Diabetes Complications. 2021 May;35(5):107882. doi: 10.1016/j.jdiacomp.2021.107882. Epub 2021 Feb 6.
The American Diabetes Association recommends that all patients at risk for hypoglycemia be prescribed glucagon. Despite this recommendation, there is evidence that prescription rates are lower than expected for patients with type 1 and type 2 diabetes. This study investigated prescription patterns for glucagon among de-identified administrative claims from OptumLabs® Data Warehouse for prescriptions between January 1, 2014 and December 31, 2014 among pharmacologically treated type 1 and 2 diabetes patients. We find that glucagon was rarely filled by patients with type 1 and type 2 diabetes, including fewer than 5% of patients with prior hypoglycemia requiring emergency healthcare utilization. Among patients with type 1 diabetes, glucagon fills were unpredictable and not targeted to highest risk patients.
美国糖尿病协会建议所有有低血糖风险的患者都开处胰高血糖素。尽管有这一建议，但有证据表明，1 型和 2 型糖尿病患者的处方率低于预期。本研究调查了 2014 年 1 月 1 日至 12 月 31 日期间 OptumLabs® Data Warehouse 中经身份识别的行政索赔中，1 型和 2 型糖尿病患者的胰高血糖素处方模式。我们发现，1 型和 2 型糖尿病患者很少开处胰高血糖素，包括先前需要紧急医疗保健的低血糖患者中，不到 5%的患者开处了胰高血糖素。在 1 型糖尿病患者中，胰高血糖素的使用情况不可预测，也没有针对高危患者。
